FORCE Blog

This blog will cover topics of interest that affect our community. Unless otherwise stated, the blog articles will be written by Sue Friedman, Executive Director of FORCE.

| More

Pancreatic cancer

November 28, 2018

You Don’t Need a Family History of Cancer to Benefit from Genetic Testing

by Sue Friedman Many people mistakenly believe that genetic testing for inherited mutations in BRCA1, BRCA2, Lynch Syndrome, and other genes is only appropriate for people with many cases of cancer in their family. National guidelines—based on the latest research—state otherwise. There are situations where a single case of cancer in a family is enough … + read more

November 9, 2018

Updates to the Practice Guidelines for Hereditary Cancer

by Piri Welcsh The National Comprehensive Cancer Network (NCCN) is a nonprofit network of 27 leading cancer centers. The NCCN publishes evidence-based guidelines for oncology. These guidelines help to set the standard of care. Guidelines are updated annually as new research is published.  Below we highlight several recent updates, which are important to the hereditary … + read more

June 17, 2018

Solving for Y: Reaching Men About Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, Prostate And Related Cancers (HBOC)

by Sue Friedman Half of all people with an inherited BRCA, ATM, CHEK2, PALB2 or other mutation associated with HBOC are men. Nevertheless, the majority of awareness, research, and resources have focused on genetic testing in women. A recent article in JAMA highlights this disparity in BRCA testing between men and women. Emerging information on … + read more

April 12, 2018

PARP Inhibitors and Hereditary Cancer: What’s New?

by Sue Friedman PARP inhibitors are drugs designed specifically to treat cancers in people with certain inherited mutations, including BRCA1 and BRCA2, among others. These drugs block an enzyme – known as PARP – used by cells to repair damage to their DNA. Although these agents seem to be most effective in people with mutations—not just … + read more

February 7, 2018

Why I Chose Immunotherapy for Pancreatic Cancer

by David Dessert I was diagnosed with stage 3 unresectable pancreatic cancer at age 48 after 5 months of ever-increasing back and abdominal pains. After a non-standard treatment with Gemzar/Cisplatin chemotherapy (because of my BRCA2 mutations), followed by chemoradiation, and 12 months later the removal of my pancreatic tumor, my surgeon told me that I … + read more

Connect with others.

Call our Helpline

Our helpline offers peer support for people concerned about hereditary cancer. All calls are confidential. Call any time.

Join a Local Group

FORCE has outreach groups throughout the United States and in Essex, United Kingdom that meet periodically to offer peer support, and share resources.

FORCE:Facing Our Risk of Cancer Empowered